Skip to content
2000
Volume 1, Issue 1
  • ISSN: 2772-6215
  • E-ISSN: 2772-6223

Abstract

Cancer’s ability to manipulate the immune system through tumor-induced immunosuppression remains a significant challenge in oncology. The tumor microenvironment (TME) employs various mechanisms, including the recruitment of immunosuppressive cells, the secretion of inhibitory cytokines, and metabolic reprogramming, to evade immune responses and impair immunotherapies. Natural killer (NK) cells, a vital component of innate immunity, exhibit potent anti-tumor activity. However, their function is often suppressed within the TME. Recent advancements in genetic engineering have enabled the development of modified NK cells with enhanced persistence, targeting, and cytotoxicity. Strategies such as chimeric antigen receptor (CAR)-NK cells, cytokine engineering, immune checkpoint blockade, and resistance to TME factors have demonstrated promising potential in overcoming immunosuppression and improving cancer therapy. This review explores the role of engineered NK cells in counteracting tumor-mediated immune evasion, current clinical advancements, and future directions in NK cell-based immunotherapy. While challenges such as persistence, scalability, and off-target effects remain, engineered NK cells offer a promising avenue for enhancing cancer treatment efficacy. This review aims to synthesize advancements in engineered NK cell therapies to overcome tumor-mediated immunosuppression.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/csci/10.2174/0127726215396606250825050837
2025-01-01
2026-02-26

  • From This Site

    /content/journals/csci/10.2174/0127726215396606250825050837
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. WangQ. ShaoX. ZhangY. ZhuM. WangF.X.C. MuJ. LiJ. YaoH. ChenK. Role of tumor microenvironment in cancer progression and therapeutic strategy.Cancer Med.20231210111491116510.1002/cam4.569836807772
     [Google Scholar]
  2. WangD.R. WuX.L. SunY.L. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response.Signal Transduct. Target. Ther.20227133110.1038/s41392‑022‑01136‑236123348
     [Google Scholar]
  3. GargP. PareekS. KulkarniP. HorneD. SalgiaR. SinghalS.S. Next-Generation immunotherapy: Advancing clinical applications in cancer treatment.J. Clin. Med.20241321653710.3390/jcm1321653739518676
     [Google Scholar]
  4. BandopadhyayS. PatranabisS. Mechanisms of HIF-driven immunosuppression in tumour microenvironment.J. Egypt. Natl. Canc. Inst.20233512710.1186/s43046‑023‑00186‑z37646847
     [Google Scholar]
  5. ColeK. Al-KadhimiZ. TalmadgeJ.E. Role of myeloid-derived suppressor cells in tumor recurrence.Cancer Metastasis Rev.202342111314210.1007/s10555‑023‑10079‑136640224
     [Google Scholar]
  6. de VisserK.E. JoyceJ.A. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth.Cancer Cell202341337440310.1016/j.ccell.2023.02.01636917948
     [Google Scholar]
  7. NeophytouC.M. PieridesC. ChristodoulouM.I. CosteasP. KyriakouT.C. PapageorgisP. The role of tumor-associated myeloid cells in modulating cancer therapy.Front. Oncol.20201089910.3389/fonc.2020.0089932656079
     [Google Scholar]
  8. ZhaoH. WuL. YanG. ChenY. ZhouM. WuY. LiY. Inflammation and tumor progression: Signaling pathways and targeted intervention.Signal Transduct. Target. Ther.20216126310.1038/s41392‑021‑00658‑534248142
     [Google Scholar]
  9. WuY. YiM. NiuM. MeiQ. WuK. Myeloid-derived suppressor cells: An emerging target for anticancer immunotherapy.Mol. Cancer202221118410.1186/s12943‑022‑01657‑y36163047
     [Google Scholar]
  10. LiL. YuR. CaiT. ChenZ. LanM. ZouT. WangB. WangQ. ZhaoY. CaiY. Effects of immune cells and cytokines on inflammation and immunosuppression in the tumor microenvironment.Int. Immunopharmacol.20208810693910.1016/j.intimp.2020.10693933182039
     [Google Scholar]
  11. NakamuraK. SmythM.J. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment.Cell. Mol. Immunol.202017111210.1038/s41423‑019‑0306‑131611651
     [Google Scholar]
  12. PandeyP. KhanF. QariH.A. UpadhyayT.K. AlkhateebA.F. OvesM. Revolutionization in cancer therapeutics via targeting major immune checkpoints PD-1, PD-L1 and CTLA-4.Pharmaceuticals202215333510.3390/ph1503033535337133
     [Google Scholar]
  13. GuptaS. RoyA. DwarakanathB.S. Metabolic cooperation and competition in the tumor microenvironment: implications for therapy.Front. Oncol.201776810.3389/fonc.2017.0006828447025
     [Google Scholar]
  14. TieY. TangF. WeiY. WeiX. Immunosuppressive cells in cancer: Mechanisms and potential therapeutic targets.J. Hematol. Oncol.20221516110.1186/s13045‑022‑01282‑835585567
     [Google Scholar]
  15. StrzelecM. DetkaJ. MieszczakP. SobocińskaM.K. MajkaM. Immunomodulation—a general review of the current state-of-the-art and new therapeutic strategies for targeting the immune system.Front. Immunol.202314112770410.3389/fimmu.2023.112770436969193
     [Google Scholar]
  16. MaslovD.V. TawagiK. KcM. SimensonV. YuanH. ParentC. BamnolkerA. GoelR. BlakeZ. MatranaM.R. JohnsonD.H. Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer.J. Immunother. Cancer202197e00226110.1136/jitc‑2020‑00226134226279
     [Google Scholar]
  17. GilesA.J. HutchinsonM.K.N.D. SonnemannH.M. JungJ. FecciP.E. RatnamN.M. ZhangW. SongH. BaileyR. DavisD. ReidC.M. ParkD.M. GilbertM.R. Dexamethasone-induced immunosuppression: Mechanisms and implications for immunotherapy.J. Immunother. Cancer2018615110.1186/s40425‑018‑0371‑529891009
     [Google Scholar]
  18. KalfeistL. GallandL. LedysF. GhiringhelliF. LimagneE. LadoireS. Impact of glucocorticoid use in oncology in the immunotherapy era.Cells202211577010.3390/cells1105077035269392
     [Google Scholar]
  19. GoodmanR.S. JohnsonD.B. BalkoJ.M. Corticosteroids and cancer immunotherapy.Clin. Cancer Res.202329142580258710.1158/1078‑0432.CCR‑22‑318136648402
     [Google Scholar]
  20. YuY. The function of NK cells in tumor metastasis and NK cell-based immunotherapy.Cancers2023158232310.3390/cancers1508232337190251
     [Google Scholar]
  21. WuS.Y. FuT. JiangY.Z. ShaoZ.M. Natural killer cells in cancer biology and therapy.Mol. Cancer202019112010.1186/s12943‑020‑01238‑x32762681
     [Google Scholar]
  22. IslamR. PupovacA. EvtimovV. BoydN. ShuR. BoydR. TrounsonA. Enhancing a natural killer: Modification of NK cells for cancer immunotherapy.Cells2021105105810.3390/cells1005105833946954
     [Google Scholar]
  23. MantessoS. GeertsD. SpanholtzJ. KučerováL. Genetic engineering of natural killer cells for enhanced antitumor function.Front. Immunol.20201160713110.3389/fimmu.2020.60713133391277
     [Google Scholar]
  24. BaldT. KrummelM.F. SmythM.J. BarryK.C. The NK cell–cancer cycle: Advances and new challenges in NK cell–based immunotherapies.Nat. Immunol.202021883584710.1038/s41590‑020‑0728‑z32690952
     [Google Scholar]
  25. LianG. MakT.S.K. YuX. LanH.Y. Challenges and recent advances in NK cell-targeted immunotherapies in solid tumors.Int. J. Mol. Sci.202123116410.3390/ijms2301016435008589
     [Google Scholar]
  26. DasA. GhoseA. NaickerK. SanchezE. ChargariC. RassyE. BoussiosS. Advances in adoptive T-cell therapy for metastatic melanoma.Curr. Res. Transl. Med.202371310340410.1016/j.retram.2023.10340437478776
     [Google Scholar]
  27. KimJ.S. KimY.G. ParkE.J. KimB. LeeH.K. HongJ.T. KimY. HanS.B. Cell-based immunotherapy for colorectal cancer with cytokine-induced killer cells.Immune Netw.20161629910810.4110/in.2016.16.2.9927162526
     [Google Scholar]
  28. BakhtiyaridovvombaygiM. YazdanparastS. KheyrandishS. SafdariS.M. Amiri SamaniF. SohaniM. JaafarianA.S. DamirchilooF. IzadpanahA. ParkhidehS. MikanikF. RoshandelE. HajifathaliA. GharehbaghianA. Harnessing natural killer cells for refractory/relapsed non-Hodgkin lymphoma: biological roles, clinical trials, and future prospective.Biomark. Res.20241216610.1186/s40364‑024‑00610‑z39020411
     [Google Scholar]
  29. GurneyM. O’DwyerM. Realizing innate potential: CAR-NK cell therapies for acute myeloid leukemia.Cancers2021137156810.3390/cancers1307156833805422
     [Google Scholar]
  30. MelaiuO. LucariniV. CifaldiL. FruciD. Influence of the tumor microenvironment on NK cell function in solid tumors.Front. Immunol.202010303810.3389/fimmu.2019.0303832038612
     [Google Scholar]
  31. Gonzalez-RodriguezA.P. Villa-ÁlvarezM. Sordo-BahamondeC. Lorenzo-HerreroS. GonzalezS. NK cells in the treatment of hematological malignancies.J. Clin. Med.2019810155710.3390/jcm810155731569769
     [Google Scholar]
  32. Mentlik JamesA. CohenA.D. CampbellK.S. Combination immune therapies to enhance anti-tumor responses by NK cells.Front. Immunol.2013448110.3389/fimmu.2013.0048124391651
     [Google Scholar]
  33. LarrosaC. MoraJ. CheungN.K. Global impact of monoclonal antibodies (mAbs) in children: A focus on anti-GD2.Cancers20231514372910.3390/cancers1514372937509390
     [Google Scholar]
  34. SarivalasisA. MorottiM. MulveyA. ImbimboM. CoukosG. Cell therapies in ovarian cancer.Ther. Adv. Med. Oncol.2021131758835921100839910.1177/1758835921100839933995591
     [Google Scholar]
  35. PazinaT. MacFarlaneA.W. BernabeiL. DulaimiE. KotcherR. YamC. BezmanN.A. RobbinsM.D. RossE.A. CampbellK.S. CohenA.D. Alterations of NK cell phenotype in the disease course of multiple myeloma.Cancers202113222610.3390/cancers1302022633435153
     [Google Scholar]
  36. TerrénI. OrrantiaA. Mikelez-AlonsoI. VitalléJ. ZenarruzabeitiaO. BorregoF. NK cell-based immunotherapy in renal cell carcinoma.Cancers202012231610.3390/cancers1202031632013092
     [Google Scholar]
  37. LiuP. ChenL. ZhangH. Natural killer cells in liver disease and hepatocellular carcinoma and the NK cell‐based immunotherapy.J. Immunol. Res.2018201811810.1155/2018/120673730255103
     [Google Scholar]
  38. ZhengW. LingS. CaoY. ShaoC. SunX. Combined use of NK cells and radiotherapy in the treatment of solid tumors.Front. Immunol.202414130653410.3389/fimmu.2023.130653438264648
     [Google Scholar]
  39. KlingemannH. The NK-92 cell line-30 years later: its impact on natural killer cell research and treatment of cancer.Cytotherapy202325545145710.1016/j.jcyt.2022.12.00336610812
     [Google Scholar]
  40. PengY. ZhangW. ChenY. ZhangL. ShenH. WangZ. TianS. YangX. CuiD. HeY. ChangX. FengZ. TangQ. MaoY. Engineering c-Met-CAR NK-92 cells as a promising therapeutic candidate for lung adenocarcinoma.Pharmacol. Res.202318810665610.1016/j.phrs.2023.10665636640859
     [Google Scholar]
  41. GongY. Klein WolterinkR.G.J. WangJ. BosG.M.J. GermeraadW.T.V. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy.J. Hematol. Oncol.20211417310.1186/s13045‑021‑01083‑533933160
     [Google Scholar]
  42. KhoshandamM. SoltaninejadH. HamidiehA.A. HosseinkhaniS. CRISPR, CAR-T, and NK: Current applications and future perspectives.Genes Dis.202411410112110.1016/j.gendis.2023.10112138545126
     [Google Scholar]
  43. ZhongY. LiuJ. Emerging roles of CAR-NK cell therapies in tumor immunotherapy: Current status and future directions.Cell Death Discov.202410131810.1038/s41420‑024‑02077‑138987565
     [Google Scholar]
/content/journals/csci/10.2174/0127726215396606250825050837
Loading
Engineered NK Cells: A Breakthrough Strategy to Overcome Cancer Immunosuppression
Curr Cell Sci 1, E27726215396606 (2025); https://doi.org/10.2174/0127726215396606250825050837
/content/journals/csci/10.2174/0127726215396606250825050837
/content/journals/csci/10.2174/0127726215396606250825050837
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): adoptive therapy; cancer immunotherapy; chimeric antigen receptor; cytokine engineering; immune checkpoints; metabolic reprogramming; NK cells; tumor microenvironment
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test